We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Halyard Health Now a Strong Buy, Portfolio Key Catalyst
Read MoreHide Full Article
On Jul 8, 2016, Zacks Investment Research upgraded Halyard Health Inc to a Zacks Rank #1 (Strong Buy).
Why the Upgrade?
Halyard’s expanding product pipeline is the primary reason behind the upgrade. The company expects to launch 10 new products across Surgical and Infection Prevention (S&IP) and Medical Devices segments in the near future.
Moreover, positive outlook on ON-Q painbuster pumps and COOLIEF interventional pain solution product lines are expected to drive top-line growth.
Meanwhile the acquisition of CORPAK Medsystems is a significant addition to Halyard’s product portfolio. CORPAK develops, manufactures and markets a broad portfolio of enteral access devices. The company reported sales of $54 million in full-year 2015.
CORPAK’s nasogastric tubes are complementary to Halyard's existing enteral feeding products. The combination will help Halyard to offer a complete enteral feeding solution for the patients and caregivers. The company recently noted that the integration of CORPAK is on track.
The takeover will boost Halyard’s full-year 2016 bottom line by a nickel. The company forecasts adjusted earnings in the range of $1.50 to $1.70 per share. For full-year 2017, the acquisition is expected to be accretive by 15 cents.
Further, Halyard has been reporting consistent earnings results. Notably, the company’s earnings have beaten the Zacks Consensus Estimate in three of the last four quarters, with an average positive surprise of 18.63%.
Estimate Revisions
The Zacks Consensus Estimate for fiscal 2016 increased couple of cents to $1.66 per share over the last 60 days. Similarly, for fiscal 2017, estimates increased 3 cents to $1.75 per share over the same time frame.
Other Stocks to Consider
One may also consider some other players in the industry that look attractive at current levels. These include Derma Sciences , ICU Medical (ICUI - Free Report) and Nxstage Medical . All the three stocks carry the same Zacks Rank as Halyard.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Halyard Health Now a Strong Buy, Portfolio Key Catalyst
On Jul 8, 2016, Zacks Investment Research upgraded Halyard Health Inc to a Zacks Rank #1 (Strong Buy).
Why the Upgrade?
Halyard’s expanding product pipeline is the primary reason behind the upgrade. The company expects to launch 10 new products across Surgical and Infection Prevention (S&IP) and Medical Devices segments in the near future.
Moreover, positive outlook on ON-Q painbuster pumps and COOLIEF interventional pain solution product lines are expected to drive top-line growth.
Meanwhile the acquisition of CORPAK Medsystems is a significant addition to Halyard’s product portfolio. CORPAK develops, manufactures and markets a broad portfolio of enteral access devices. The company reported sales of $54 million in full-year 2015.
HALYARD HEALTH Price and Consensus
HALYARD HEALTH Price and Consensus | HALYARD HEALTH Quote
CORPAK’s nasogastric tubes are complementary to Halyard's existing enteral feeding products. The combination will help Halyard to offer a complete enteral feeding solution for the patients and caregivers. The company recently noted that the integration of CORPAK is on track.
The takeover will boost Halyard’s full-year 2016 bottom line by a nickel. The company forecasts adjusted earnings in the range of $1.50 to $1.70 per share. For full-year 2017, the acquisition is expected to be accretive by 15 cents.
Further, Halyard has been reporting consistent earnings results. Notably, the company’s earnings have beaten the Zacks Consensus Estimate in three of the last four quarters, with an average positive surprise of 18.63%.
Estimate Revisions
The Zacks Consensus Estimate for fiscal 2016 increased couple of cents to $1.66 per share over the last 60 days. Similarly, for fiscal 2017, estimates increased 3 cents to $1.75 per share over the same time frame.
Other Stocks to Consider
One may also consider some other players in the industry that look attractive at current levels. These include Derma Sciences , ICU Medical (ICUI - Free Report) and Nxstage Medical . All the three stocks carry the same Zacks Rank as Halyard.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>